

103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 HB5420

Introduced 2/9/2024, by Rep. Kimberly Du Buclet

SYNOPSIS AS INTRODUCED:

410 ILCS 240/3.6 new

Amends the Newborn Metabolic Screening Act. Provides for the screening and testing of all newborns for Guanidinoacetate Methyltransferase (GAMT) deficiency. Sets forth requirements that must be met before the screening and testing begin. Authorizes the Department of Public Health to implement an additional fee for the screening prior to beginning testing in order to accumulate resources to implement the amendatory Act.

LRB103 37927 CES 68059 b

1 AN ACT concerning health.

Be it enacted by the People of the State of Illinois, represented in the General Assembly:

- Section 5. The Newborn Metabolic Screening Act is amended by adding Section 3.6 as follows:
- 6 (410 ILCS 240/3.6 new)
- 7 <u>Sec. 3.6. Guanidinoacetate Methyltransferase (GAMT)</u>
- 8 <u>deficiency.</u>

14

- 9 <u>(a) In accordance with the timetable specified in this</u>
 10 <u>Section, the Department shall provide all newborns with</u>
 11 <u>screening tests for the presence of Guanidinoacetate</u>
 12 <u>Methyltransferase (GAMT) deficiency. The testing shall begin</u>
- within 12 months after the occurrence of all of the following:
- 15 appropriate performance specifications as defined under

(1) the establishment and verification of relevant and

- 16 <u>the federal Clinical Laboratory Improvement Amendments and</u>
- 17 <u>regulations</u> thereunder for Federal Drug
- 18 <u>Administration-cleared or in-house developed methods</u>,
- 19 performed under an institutional review board approved
- 20 <u>protocol, if required;</u>
- 21 (2) the availability of quality assurance testing and
- 22 <u>comparative threshold values for GAMT;</u>
- 23 (3) the acquisition and installment by the Department

Τ	of the equipment necessary to implement the initial prior
2	and statewide volume of screening tests for GAMT;
3	(4) the establishment of precise threshold values
4	ensuring defined disorder identification for GAMT;
5	(5) the authentication of pilot testing achieving each
6	milestone described in items (a) through (d) of this
7	Section for GAMT; and
8	(6) the authentication of achieving the potential of
9	high throughput standards for statewide volume of the GAMT
10	screening test concomitant with each milestone described
11	in items (1) through (4) of this Section.
12	(b) The Department may implement an additional fee for the
13	screening prior to beginning the testing in order to
14	accumulate the resources for start-up and other costs
15	associated with implementation of the screening and thereafter
16	to support the costs associated with screening and follow-up
17	programs for GAMT.